X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/05/2858365/0/en/HUTCHMED-Highlights-Data-to-be-Presented-at-AACR-Congress-2024.html
https://www.globenewswire.com/news-release/2024/04/02/2855618/0/en/HUTCHMED-and-Innovent-Jointly-Announce-NDA-Acceptance-in-China-for-Fruquintinib-Combination-with-Sintilimab-for-the-Treatment-of-Advanced-Endometrial-Cancer-with-Priority-Review-St.html
https://www.globenewswire.com/news-release/2024/03/28/2853678/0/en/HUTCHMED-Announces-Savolitinib-sNDA-Accepted-in-China-for-Treatment-Na%C3%AFve-or-Previously-Treated-Patients-with-Locally-Advanced-or-Metastatic-MET-Exon-14-NSCLC.html
https://www.globenewswire.com/news-release/2024/03/22/2850714/0/en/HUTCHMED-Initiates-Registration-Stage-of-the-ESLIM-02-Phase-II-III-Trial-of-Sovleplenib-for-Warm-Antibody-Autoimmune-Hemolytic-Anemia-in-China.html
https://www.globenewswire.com//news-release/2024/02/28/2836757/0/en/HUTCHMED-Reports-2023-Full-Year-Results-and-Provides-Business-Updates.html
https://www.globenewswire.com//news-release/2024/02/07/2824809/0/en/HUTCHMED-Highlights-Presentation-of-Phase-III-Data-on-Fruquintinib-in-Second-Line-Gastric-Cancer-at-ASCO-Plenary-Series-Session.html
https://www.globenewswire.com//news-release/2024/02/02/2822633/0/en/HUTCHMED-Announces-that-Inmagene-Exercises-Option-to-License-Two-Drug-Candidates-as-Part-of-Strategic-Partnership.html
https://www.prnewswire.com/news-releases/inmagene-exercises-option-to-obtain-exclusive-worldwide-license-for-img-007-and-img-004-from-hutchmed-302051787.html
https://www.globenewswire.com//news-release/2024/02/01/2821722/0/en/HUTCHMED-to-Announce-2023-Final-Results.html
Market Place
Share 
